2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow

Core Viewpoint - Johnson & Johnson (J&J) has transitioned by spinning off its consumer health business to focus on innovative medicine and medtech, despite facing challenges from the loss of exclusivity of its top-selling drug, Stelara [1][2] Group 1: Company Performance - J&J has shown resilience by managing growth in its two main businesses despite the decline of Stelara [2] - The company's shares have increased by 15% this year, contrasting with the S&P 500's decline, indicating strong performance during uncertain market conditions [4] - J&J has 28 platforms or products generating at least $1 billion annually, allowing it to move past the Stelara exclusivity loss [5] Group 2: Financial Metrics - J&J's market capitalization is $572 billion, with a current share price range between $235.50 and $239.11 [6] - The company has a gross margin of 67.97% and a dividend yield of 2.19% [6] Group 3: Dividend Growth - J&J is recognized as a Dividend King, having increased its dividend for over 50 years, demonstrating a commitment to shareholder returns [7] - The company pays a dividend of $5.20, which is higher than the S&P 500's dividend yield of 1.1%, making it an attractive option for passive income [9]